Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajat Kumar

Showing results (321-330 of 341) with videos related to

Pageof 35
Sort By:
Blood Advances|November 20, 2024
PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantationNihar Desai, Majed Altareb, Mats Remberger, et al.
Blood Advances|January 4, 2018
ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemiaLawrence Faulkner, Cornelio Uderzo, Sadaf Khalid, et al.
Bone Marrow Transplantation|December 16, 2022
Impact of hematopoietic cell transplant frailty scale on transplant outcome in adultsMaria Queralt Salas, Eshetu G Atenafu, Ivan Pasic, et al.
Leukemia & Lymphoma|October 19, 2016
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials GroupMatthew D Seftel, John Kuruvilla, Tom Kouroukis, et al.
Bone Marrow Transplantation|August 24, 2023
HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantationMaria Queralt Salas, Eshetu G Atenafu, Ivan Pasic, et al.
British Journal of Haematology|September 14, 2025
Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatmentSergio Rodriguez-Rodriguez, Nihar Desai, Carol Chen, et al.
Transplantation and Cellular Therapy|April 2, 2021
Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in MyelofibrosisElliot Smith, Jingyue Huang, Auro Viswabandya, et al.
Blood Advances|April 14, 2020
Life expectancy and risk factors for early death in patients with severe thalassemia syndromes in South IndiaRakesh Dhanya, Amit Sedai, Kumari Ankita, et al.
American Journal of Ophthalmology|February 22, 2025
Diagnostic Accuracy of IDX-DR for Detecting Diabetic Retinopathy: A Systematic Review and Meta-AnalysisZaid Khan, Abhay M Gaidhane, Mahendra Singh, et al.
Annals of Hematology|October 5, 2017
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registryBrett L Houston, Jennifer Jayakar, Richard A Wells, et al.
Pageof 35

Showing results (321-330 of 341) with videos related to

Sort By:
Pageof 35
Blood Advances|November 20, 2024
PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantationNihar Desai, Majed Altareb, Mats Remberger, et al.
Blood Advances|January 4, 2018
ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemiaLawrence Faulkner, Cornelio Uderzo, Sadaf Khalid, et al.
Bone Marrow Transplantation|December 16, 2022
Impact of hematopoietic cell transplant frailty scale on transplant outcome in adultsMaria Queralt Salas, Eshetu G Atenafu, Ivan Pasic, et al.
Leukemia & Lymphoma|October 19, 2016
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials GroupMatthew D Seftel, John Kuruvilla, Tom Kouroukis, et al.
Bone Marrow Transplantation|August 24, 2023
HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantationMaria Queralt Salas, Eshetu G Atenafu, Ivan Pasic, et al.
British Journal of Haematology|September 14, 2025
Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatmentSergio Rodriguez-Rodriguez, Nihar Desai, Carol Chen, et al.
Transplantation and Cellular Therapy|April 2, 2021
Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in MyelofibrosisElliot Smith, Jingyue Huang, Auro Viswabandya, et al.
Blood Advances|April 14, 2020
Life expectancy and risk factors for early death in patients with severe thalassemia syndromes in South IndiaRakesh Dhanya, Amit Sedai, Kumari Ankita, et al.
American Journal of Ophthalmology|February 22, 2025
Diagnostic Accuracy of IDX-DR for Detecting Diabetic Retinopathy: A Systematic Review and Meta-AnalysisZaid Khan, Abhay M Gaidhane, Mahendra Singh, et al.
Annals of Hematology|October 5, 2017
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registryBrett L Houston, Jennifer Jayakar, Richard A Wells, et al.
Pageof 35